China Universal Asset Management Co., Ltd. Eiger Bio Pharmaceuticals, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$0.28 - $0.93 $154 - $514	553 Added 95.34%	1,133 $0
Q3 2023 Oct 30, 2023	BUY	$0.28 - $0.93 $154 - $514	553 Added 95.34%	1,133 $0
Q2 2023 May 21, 2024	SELL	$0.55 - $1.26 $9 - $21	-17 Reduced 2.85%	580 $0
Q2 2023 Jul 27, 2023	SELL	$0.55 - $1.26 $9 - $21	-17 Reduced 2.85%	580 $0
Q1 2023 May 21, 2024	BUY	$0.89 - $2.52 $133 - $378	150 Added 33.56%	597 $0
Q1 2023 Apr 27, 2023	BUY	$0.89 - $2.52 $133 - $378	150 Added 33.56%	597 $1,000
Q4 2022 May 21, 2024	BUY	$1.02 - $7.48 $455 - $3,343	447 New	447 $0
Q4 2022 Jan 31, 2023	BUY	$1.02 - $7.48 $35 - $261	35 Added 8.5%	447 $1,000
Q3 2022 Oct 21, 2022	BUY	$6.04 - $9.66 $2,488 - $3,979	412 New	412 $3,000

Others Institutions Holding EIGR

# of Institutions

Shares Held

748K

Call Options Held

Put Options Held

View Full List

About Eiger BioPharmaceuticals, Inc.

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

More about EIGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account